explore -WSS

explore

author：leisure time 2025-09-30 16:28:30 - browse：9

Dr. Peter Bach — Peter Bach, shown at the 2019 STAT summit, is now chief medical officer of Delfi. Emilie Pickering for STAT

Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect cancer, said on Monday that it is launching a new test, FirstLook Lung, to try to identify people who could most benefit from lung cancer screening.

The approach represents a new one in the field of liquid biopsy, in which DNA fragments in blood are used to detect or learn about tumors. Grail, another company developing a blood test for cancer screening, has insisted that its product would be best used to detect multiple cancers at once. Other companies, including Exact Sciences and Freenome, are developing tests that would focus on detecting colorectal cancer. But Delfi appears to be the first to focus first on lung cancer, the leading cause of cancer death.

Delfi’s executives, in an interview with STAT, were clear that they view the initial launch as an opportunity to gather information, and not a real commercial coming out. The test will likely become available in limited ways with specific partners and will not initially be covered by insurance. Delfi declined to reveal a specific price, but said that its early access customers, which it is not yet disclosing, will be able to use FirstLook Lung for several hundred dollars. Such a rollout does not require approval from the Food and Drug Administration, which Delfi does not have.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： What will save rural psychiatry services? Higher Medicaid payments

WSS

Ultragenyx gene therapy for rare liver ailment succeeds in late

Heat waves linked to early deliveries, preterm births in new study

Heat waves linked to early deliveries, preterm births in new study

With trial win, GSK could get blood cancer drug back on market

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Insmed lung disease drug hits target in key Phase 3 trial

entertainment

explore

knowledge

Medical leaders decry Supreme Court decision on affirmative action

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Hepatitis C has a cure — but many Americans still lack access to it

Average age of first period drops to 11.9 years, study shows

Duchenne breakthrough therapy leaves behind pioneering families

At ASCO, AstraZeneca reports strong data for breast cancer drug

ChatGPT in medicine: STAT answers readers' burning questions

Health insurers say they are turning to AI to cut costs, improve care

Peter Hotez and the public health issue of online harassment

First Opinion Podcast: What happens when kids become caregivers?

focus

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Focused ultrasound for uterine fibroids: an uphill battle

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Lab trade group sues FDA to halt regulation of lab

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Insmed lung disease drug hits target in key Phase 3 trial

leisure time

leisure time

hotspot

knowledge